Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
US Health Company Kenvue Upgrades Cooperation With Chinese Drugstore Chain
Kenvue's Skin Health & Beauty Segment Likely to Remain Under Pressure, RBC Says
Analysts Agree That Kenvue's Neutrogena Needs a Face-lift
Kenvue Price Target Announced at $24.00/Share by RBC Capital
RBC Capital Downgrades Kenvue(KVUE.US) to Hold Rating, Maintains Target Price $24
Express News | Kenvue Inc : RBC Cuts to Sector Perform From Outperform
Express News | Kenvue Inc : Jefferies Initiates Coverage With Buy Rating; Target Price $27
Kenvue Is Maintained at Neutral by Piper Sandler
Kenvue Analyst Ratings
Citigroup Adjusts Price Target on Kenvue to $23 From $21, Maintains Neutral Rating
Piper Sandler Sticks to Its Hold Rating for Kenvue, Inc. (KVUE)
Express News | Kenvue Drives Climate Action Strategy Forward
Kenvue Inc. (KVUE): A Good Hair Care Stock To Consider Buying Now
Express News | Kenvue Inc : Piper Sandler Raises Target Price to $21 From $20
Daily short sale tracking: Palantir's short volume increased by 102 million, with a short sale ratio of 24%
Daily short sale tracking: NVIDIA's short volume increased by 9 million, with a short sale ratio of 8%
US Consumer Health Company Kenvue Eyes Innovation to Tap China's Growing Market
28 Top Rated U.S. Growth Stocks Month-to-date in Anticipation of Fed Cuts
Kenvue Stock: Is KVUE Outperforming the Consumer Defensive Sector?